Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Everolimus
  • Hypercholesterolemia
  • Hyperglycemia
  • Kidney Neoplasms

abstract

  • Hyperglycemia and hypercholesterolemia were observed in low numbers of patients, and although these events might be associated with improved response to everolimus, the differences were not significant. These findings should be validated with prospective biomarker studies.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5063024

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2016.04.011

PubMed ID

  • 27287020

Additional Document Info

start page

  • 406

end page

  • 414

volume

  • 14

number

  • 5